4D Molecular Therapeutics, Inc. (FDMT)

NASDAQHealth CareBiotechnologySnapshot 2026-09-04

$14.97+1.84%

Close 2026-09-04 · 1-day change

QuarterlyIQ Insights · FDMT

Financials

Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.

Income Statement

Period

View

Order

Figures in millions of None, except per-share and ratios.

	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenues
Revenues	—	85.2	0.0	20.7	3.1	18.0	13.6
Total Revenues	—	85.2	0.0	20.7	3.1	18.0	13.6
Operating Expenses & Income
Operating Income	(197.1)	(159.5)	(187.8)	(112.9)	(110.0)	(71.3)	(56.7)
Earnings from Continuing Operations
Interest & Investment Income	18.2	19.5	27.1	12.2	2.6	0.1	0.2
Other Non-Operating Income / Expenses	17.9	19.4	27.0	12.0	2.5	0.0	(0.0)
Income Tax Expense	—	—	—	0.0	0.0	0.0	0.0
Net Income
Net Income	(179.2)	(140.1)	(160.9)	(100.8)	(107.5)	(71.3)	(56.7)
Per Share
Basic EPS	(2.55)	(2.42)	(2.98)	(2.58)	(3.32)	(2.57)	—
Diluted EPS	(2.55)	(2.42)	(2.98)	(2.58)	(3.32)	(2.57)	—
Basic Weighted Avg Shares	70.3	57.9	53.9	39.1	32.4	27.7	—
Diluted Weighted Avg Shares	70.3	57.9	53.9	39.1	32.4	27.7	—
Supplemental
EBITDA	—	(154.9)	(183.2)	(108.7)	(107.6)	(69.8)	(55.2)
EBIT	(197.1)	(159.5)	(187.8)	(112.9)	(110.0)	(71.3)	(56.7)

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.